1. Home
  2. ACAD vs AUGO Comparison

ACAD vs AUGO Comparison

Compare ACAD & AUGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$28.38

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Logo Aura Minerals Inc.

AUGO

Aura Minerals Inc.

HOLD

Current Price

$75.87

Market Cap

4.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
AUGO
Founded
1993
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
4.8B
IPO Year
2000
2009

Fundamental Metrics

Financial Performance
Metric
ACAD
AUGO
Price
$28.38
$75.87
Analyst Decision
Buy
Strong Buy
Analyst Count
22
3
Target Price
$30.55
$67.60
AVG Volume (30 Days)
1.7M
798.1K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
1.97%
EPS Growth
69.12
N/A
EPS
0.20
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
$91.05
Revenue Next Year
$11.70
$17.09
P/E Ratio
$141.95
N/A
Revenue Growth
40.45
N/A
52 Week Low
$19.69
$26.63
52 Week High
$29.85
$110.32

Technical Indicators

Market Signals
Indicator
ACAD
AUGO
Relative Strength Index (RSI) 61.99 67.27
Support Level $25.00 $71.04
Resistance Level N/A $77.01
Average True Range (ATR) 0.95 3.16
MACD 0.09 2.27
Stochastic Oscillator 66.04 87.75

Price Performance

Historical Comparison
ACAD
AUGO

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About AUGO Aura Minerals Inc.

Aura Minerals Inc is a mid-tier gold and copper production company focused on the development and operation of gold and base metal projects in the Americas. The company's operating segments include: Minosa Mine, Apoena Mine, the Aranzazu Mine, Almas Mine, Borborema Mine and Serra Grande Mine. It derives maximum revenue from Aranzazu Mine. The company's growth projects include: Matupa in Brazil, and Era Dorada in Guatemala. whereas its exploration projects include: Carajas, in Brazil, and Tolda Fria in Colombia.

Share on Social Networks: